

=====

Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866)  
217-9197 (toll free).

Reviewer: Anne Corrigan

Timestamp: [year=2008; month=8; day=7; hr=17; min=52; sec=22; ms=327; ]

=====

|                 |          |             |     |
|-----------------|----------|-------------|-----|
| Application No: | 10578470 | Version No: | 1.0 |
|-----------------|----------|-------------|-----|

Input Set:

Output Set:

|                        |                                 |
|------------------------|---------------------------------|
| Started:               | 2008-07-02 13:01:58.730         |
| Finished:              | 2008-07-02 13:01:58.805         |
| Elapsed:               | 0 hr(s) 0 min(s) 0 sec(s) 75 ms |
| Total Warnings:        | 0                               |
| Total Errors:          | 0                               |
| No. of SeqIDs Defined: | 4                               |
| Actual SeqID Count:    | 4                               |

# SEQUENCE LISTING

<110> Novartis AG

<120> Use of fibroblast growth factor fragments

<130> 4-33264A

<140> 10578470

<141> 2008-07-02

<160> 4

<170> PatentIn version 3.1

<210> 1

<211> 251

<212> PRT

<213> Homo sapiens

<400> 1

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Leu | Gly | Ala | Arg | Leu | Arg | Leu | Trp | Val | Cys | Ala | Leu | Cys | Ser | Val |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Cys | Ser | Met | Ser | Val | Leu | Arg | Ala | Tyr | Pro | Asn | Ala | Ser | Pro | Leu | Leu |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gly | Ser | Ser | Trp | Gly | Gly | Leu | Ile | His | Leu | Tyr | Thr | Ala | Thr | Ala | Arg |
|     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Ser | Tyr | His | Leu | Gln | Ile | His | Lys | Asn | Gly | His | Val | Asp | Gly | Ala |
|     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Pro | His | Gln | Thr | Ile | Tyr | Ser | Ala | Leu | Met | Ile | Arg | Ser | Glu | Asp | Ala |
| 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |

Gly Phe Val Val Ile Thr Gly Val Met Ser Arg Arg Tyr Leu Cys Met  
85 90 95

Asp Phe Arg Gly Asn Ile Phe Gly Ser His Tyr Phe Asp Pro Glu Asn  
100 105 110

Cys Arg Phe Gln His Gln Thr Leu Glu Asn Gly Tyr Asp Val Tyr His  
115 120 125

Ser Pro Gln Tyr His Phe Leu Val Ser Leu Gly Arg Ala Lys Arg Ala  
130 135 140

Phe Leu Pro Gly Met Asn Pro Pro Pro Tyr Ser Gln Phe Leu Ser Arg  
145 150 155 160

Arg Asn Glu Ile Pro Leu Ile His Phe Asn Thr Pro Ile Pro Arg Arg  
165 170 175

His Thr Arg Ser Ala Glu Asp Asp Ser Glu Arg Asp Pro Leu Asn Val  
180 185 190

Leu Lys Pro Arg Ala Arg Met Thr Pro Ala Pro Ala Ser Cys Ser Gln  
195 200 205

Glu Leu Pro Ser Ala Glu Asp Asn Ser Pro Met Ala Ser Asp Pro Leu  
210 215 220

Gly Val Val Arg Gly Gly Arg Val Asn Thr His Ala Gly Gly Thr Gly  
225 230 235 240

Pro Glu Gly Cys Arg Pro Phe Ala Lys Phe Ile  
245 250

<210> 2

<211> 75

<212> PRT

<213> Homo sapiens

<400> 2

His Thr Arg Ser Ala Glu Asp Asp Ser Glu Arg Asp Pro Leu Asn Val  
1 5 10 15

Leu Lys Pro Arg Ala Arg Met Thr Pro Ala Pro Ala Ser Cys Ser Gln  
20 25 30

Glu Leu Pro Ser Ala Glu Asp Asn Ser Pro Met Ala Ser Asp Pro Leu  
35 40 45

Gly Val Val Arg Gly Gly Arg Val Asn Thr His Ala Gly Gly Thr Gly  
50 55 60

Pro Glu Gly Cys Arg Pro Phe Ala Lys Phe Ile  
65 70 75

<210> 3

<211> 756

<212> DNA

<213> Homo sapiens

<400> 3

atgttggggg cccgcctcag gctctgggtc tgtgccttgt gcagcgtctg cagcatgagc 60

gtcctcagag cctatcccaa tgcctcccca ctgctcggct ccagctgggg tggcctgata 120

cacctgtaca cagccacagc caggaacagc taccacctgc agatccacaa gaatggccat 180

gtggatggcg caccceatca gaccatctac agtgccttga tgatcagatc agaggatgct 240

ggcttttgtg tgattacagg tgtgatgagc agaagatacc tctgcatgga tttcagaggc 300

aacatttttg gatcacacta tttcgacccg gagaactgca ggttccaaca ccagacgctg 360

gaaaacgggt acgacgtcta cactctcct cagtatcact tcttggtcag tctgggccgg 420

gcgaagagag ccttcctgcc aggcataaac ccacccccgt actcccagtt cctgtcccgg 480

aggaacgaga tccccctaat tcacttcaac acccccatac cagggcggca caccggagc 540

gccgaggacg actcggagcg ggacccccctg aacgtgctga agccccgggc ccggatgacc 600

ccggccccgg cctcctgttc acaggagctc ccgagcgccg aggacaacag cccgatggcc 660

agtgacccat taggggtggt caggggcggt cgagtgaaca cgcacgctgg gggaacgggc 720

ccggaaggct gccgccctt cgccaagttc atctag 756

<210> 4

<211> 228

<212> DNA

<213> Homo sapiens

<400> 4

|   |     |
|---|-----|
| cacacccgga ggcgcgagga cgactcggag cgggaccccc tgaacgtgct gaagccccgg | 60  |
| gcccggatga ccccggtccc gccctcctgt tcacaggagc tcccgagcgc cgaggacaac | 120 |
| agcccgatgg ccagtgacct attaggggtg gtcagggggc gtcgagtgaa cacgcacgct | 180 |
| ggggggaacgg gcccggaagg ctgccgcccc ttcgccaagt tcattctag            | 228 |